Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

Abstract Background Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently unclear. Methods Patients with metastatic or unresectable UM treated with ip...

Full description

Bibliographic Details
Main Authors: Markus V. Heppt, Teresa Amaral, Katharina C. Kähler, Lucie Heinzerling, Jessica C. Hassel, Markus Meissner, Nicole Kreuzberg, Carmen Loquai, Lydia Reinhardt, Jochen Utikal, Evelyn Dabrowski, Anja Gesierich, Claudia Pföhler, Patrick Terheyden, Kai-Martin Thoms, Lisa Zimmer, Thomas K. Eigentler, Michael C. Kirchberger, Henner M. Stege, Friedegund Meier, Max Schlaak, Carola Berking
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Ipilimumab
Nivolumab
Combined immune checkpoint blockade
Uveal melanoma
Biomarker
Online Access:http://link.springer.com/article/10.1186/s40425-019-0800-0

Internet

http://link.springer.com/article/10.1186/s40425-019-0800-0

Similar Items